This clinical study will evaluate the safety, reactogenicity, and immunogenicity of monovalent mRNA-1982, a messenger ribonucleic acid (mRNA) vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years old.
In good general health in the opinion of the investigator as determined by medical evaluation including medical history and physical examination at screening.
Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic.
Have chronic illness related to Lyme disease or an active symptomatic Lyme disease infection as suspected or diagnosed by a physician.
Received treatment for Lyme disease within the prior 3 months.
Previously vaccinated against Lyme disease or participated in the past in any vaccine study for Lyme disease.
ModernaTX, Inc.
Lead sponsor